Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

First-in-human study investigates HJV inhibitor DISC-0974 for anemia of inflammation

July 28, 2021

FXa-DOAC reversal with no thrombogenic potential seen with VMX-C001

July 28, 2021

ExCellThera initiates phase I study of ECT-001-CB in sickle cell disease

July 23, 2021

Chinese researchers patent coagulation factor XIa inhibitors

July 23, 2021

FDA places clinical hold on phase I/II study of SIG-001 in hemophilia A

July 12, 2021

FDA clears IND for ASC-618 gene therapy for hemophilia A

July 8, 2021

Shenzhen Salubris Pharmaceuticals patents factor XIa inhibitors

June 30, 2021

Keros reports preliminary phase II data on KER-050 for MDS

June 23, 2021

Etavopivat improves hematologic and hemolytic parameters in patients with sickle cell disease

June 21, 2021

Shenzhen Salubris Pharmaceuticals synthesizes FXIa inhibitors

June 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...